Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 19 Esophageal Squamous Cell Carcinoma 5 Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Rectal Neoplasms 3 Head and Neck Neoplasms 3 Carcinoma, Hepatocellular 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma 2 Ovarian Neoplasms 2 Neoplasm, Residual 2 Neoplasm Metastasis 2 Lymphoma, Large B-Cell, Diffuse 2 Lung Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Waldenstrom Macroglobulinemia 1 Urinary Bladder Neoplasms 1 Turcot syndrome 1 Testicular Neoplasms 1 Surgery 1 Stress, Psychological 1 Squamous Cell Carcinoma of External Auditory Canal 1 Solitary Fibrous Tumor, Pleural 1 Seminoma 1 Recurrence 1 Postoperative Complications 1

Interventions

Radiotherapy 4 osimertinib 3 aflutinib 3 Radiosurgery 3 Pemetrexed 3 Drug Therapy 3 Carboplatin 3 toripalimab 2 pembrolizumab 2 Docetaxel 2 tislelizumab 1 sugemalimab 1 lenvatinib 1 cemiplimab 1 brigatinib 1 Vinorelbine 1 Tyrosine Kinase Inhibitors 1 Surgical Procedures, Operative 1 S 1 (combination) 1 Platinum Compounds 1 Platinum 1 Pharmaceutical Preparations 1 Paclitaxel 1 Neoadjuvant Therapy 1 JDQ443 1 Immune Checkpoint Inhibitors 1 HM781-36B 1 Gemcitabine 1 Diphenhydramine 1 Cryotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NSCLC × Neoadjuvant Therapy × 1 year × Clear all

NCT07089199 2025-07-28

TitAN

Qilu Hospital of Shandong University

Phase 2 Not yet recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡